US Patent Issued to Eisai R&D Management on Dec. 23 for "Biomarkers for a therapy comprising a sorafenib compound" (Japanese, American Inventors)

ALEXANDRIA, Va., Dec. 23 -- United States Patent no. 12,504,431, issued on Dec. 23, was assigned to Eisai R&D Management Co. Ltd. (Tokyo).

"Biomarkers for a therapy comprising a sorafenib compound" was invented by Yasuhiro Funahashi (Tokyo), Yukinori Minoshima (Tsukuba, Japan), Michio Kanekiyo (Edgewater, N.J.), Saori Miyano (Tsukubamirai, Japan) and Taisuke Hoshi (Tsukubamirai, Japan).

According to the abstract* released by the U.S. Patent & Trademark Office: "Biomarkers are provided that predict whether a subject having a hepatocellular carcinoma is responsive to a therapy comprising sorafenib or a pharmaceutically acceptable salt thereof. The biomarkers, compositions, and methods described herein are useful in selecting appropriate tre...